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Abstract
Chemokines are small secreted proteins with important roles in immune responses. They consist of a conserved three-
dimensional (3D) structure, so-called IL8-like chemokine fold, which is supported by disulfide bridges characteristic of this
protein family. Sequence- and profile-based computational methods have been proficient in discovering novel chemokines
by making use of their sequence-conserved cysteine patterns. However, it has been recently shown that some chemokines
escaped annotation by these methods due to low sequence similarity to known chemokines and to different arrangement
of cysteines in sequence and in 3D. Innovative methods overcoming the limitations of current techniques may allow the
discovery of new remote homologs in the still functionally uncharacterized fraction of the human genome. We report
a novel computational approach for proteome-wide identification of remote homologs of the chemokine family that uses
fold recognition techniques in combination with a scaffold-based automatic mapping of disulfide bonds to define a 3D
profile of the chemokine protein family. By applying our methodology to all currently uncharacterized human protein
sequences, we have discovered two novel proteins that, without having significant sequence similarity to known
chemokines or characteristic cysteine patterns, show strong structural resemblance to known anti-HIV chemokines. Detailed
computational analysis and experimental structural investigations based on mass spectrometry and circular dichroism
support our structural predictions and highlight several other chemokine-like features. The results obtained support their
functional annotation as putative novel chemokines and encourage further experimental characterization. The identification
of remote homologs of human chemokines may provide new insights into the molecular mechanisms causing pathologies
such as cancer or AIDS, and may contribute to the development of novel treatments. Besides, the genome-wide
applicability of our methodology based on 3D protein family profiles may open up new possibilities for improving and
accelerating protein function annotation processes.
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Introduction
The fraction of uncharacterized proteins in the human
proteome currently still comprises more than 75% in the UniProt
knowledgebase, which is the most comprehensive available protein
sequence database (all proteins in UniProt/TrEMBL) [1]. Current
techniques to predict the function of uncharacterized proteins rely
mainly on their sequence homology to already characterized
proteins [2]. More advanced methods use sequence-profile [3] or
profile-profile alignments [4]. Although these methods have
significantly improved in terms of detection of remote homology
[5], still more than 20% of the human proteome has not been
annotated (i.e. no InterPro domain annotation in UniProt) because
no characterized homologs could be identified with the necessary
statistical significance.
Protein structural homology is often strong in the absence of
significant sequence homology [6]. Structure-based fold recog-
nition methods have been shown to be useful to recognize
possible structural resemblances even at levels of non-recogniz-
able sequence similarity (below 20–30% [7]). Threading
techniques are able to predict the 3D structure of a query
protein by pulling its amino acid sequence through the
backbone of experimentally determined protein 3D structures
without relying on sequence similarity. Thus, these techniques
can complement sequence-based methods in structural and
functional annotation of proteins. Detection of very remote
homology by using these techniques has been successfully
demonstrated in previous applications [8–11]. In our previous
work, we discovered a novel remote member of the chemokine
family by applying fold recognition methods, the human
chemokine CXCL17 [12], which is the last member of the
CXC chemokine family being so far identified [13]. Chemo-
kines are secreted signal proteins with significant impact on the
function of the immune system and are important molecules in
inflammatory responses. Some chemokines have also been
shown to play a role in processes like angiogenesis [14],
haematopoiesis [15], inhibition of HIV infection, tumor growth
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e36151[16,17] and apoptosis [18]. Furthermore, they are very well
suited for the development of small molecule inhibitors with
strong therapeutic potential as they act through G protein–
coupled receptors [19].
Chemokines share a conserved 3D structure, the so-called IL8-
like chemokine fold, which is stabilized by cysteine residues
forming intra-molecular disulfide bonds. Interestingly, the pre-
dicted IL8-like chemokine structure of CXCL17 revealed disulfide
bonds in non-canonical regions in 3D structure but still
maintaining an active fold. The low sequence similarity to other
known members of the family and its cysteine patterns differing
from those in known chemokines are the reasons why chemokine
CXCL17 escaped annotation by standard sequence-based meth-
ods [12]. Current standard techniques that can be applied to
identify chemokines include the ChemoPred web server [20],
a machine learning technique, Hidden Markov Models of
SMART [21,22] and Pfam [23] and PROSITE’s chemokine
profiles and patterns [24] (Supporting Text S1 I and Table S1).
However, the results that can be obtained by these methods are
limited to the diversity of the training dataset, which originates
almost exclusively from sequence-based approaches. Thus, these
methods can hardly detect structural resemblance without detect-
able sequence similarity.
The identification of CXCL17 by threading-based computa-
tional means motivated us to perform a more systematic search in
the human proteome to discover other possible remote members
of the chemokine family that, like CXCL17, might have been so
far overlooked. Several threading techniques are available to
detect structural resemblances in proteins [5], including the
methodology we used to discover CXCL17 [12]. However, none
of these resources offers the possibility to automatically screen
thousands of sequences for structural resemblances in combination
with scaffold-based mapping of disulfide bonds patterns that may
be indicative of a functional fold in 3D.
Here, we present a novel computational approach based on
3D protein family profiles for searching in a proteome-wide
automatic fashion for still uncharacterized human proteins that
could fold into a functional IL8-like chemokine architecture and
that may have not been yet discovered because of having
remote sequence similarity to known chemokines and a different
cysteine pattern in sequence and in 3D. We combine threading
techniques for structure prediction with an automatic method
for scaffold-based mapping of disulfide bonds in 3D as
a functional descriptor. We apply our methodology to all
currently uncharacterized human protein sequences from the
UniProt database, and we identify two novel human proteins
that present a strong structural resemblance to other known
chemokines, in particular two anti-HIV chemokines. We build
3D molecular models of these proteins and perform detailed
structure-based computational analysis in combination with
experimental work based on mass spectrometry and circular
dichroism, which support our structural predictions and
highlight several other chemokine-like features. The results
obtained substantiate the annotation of these two novel proteins
as putative human chemokines and should awaken great interest
in their further experimental characterization.
Results and Discussion
The general scheme of our computational approach and the
steps followed in our work to discover novel human protein
sequences that could potentially be remote chemokine homologs
are summarized in Figure 1.
Proteome-wide 3D Profile-based Computational
Screening
Sequence data extraction and pre-filtering. A search in
UniProt for human protein sequences still uncharacterized was
performed with the criteria of selecting sequences containing at
least two cysteine residues, as the formation of disulfide bonds is
a requirement for a functional IL8-like chemokine fold (for details
see Materials and Methods section 1). This search resulted in
a total of 6,933 protein sequences (Figure 1, step 1), which were
taken as input dataset for our automatic analysis. Next, and in
order to discard from our studies those sequences that could be
already structurally annotated, we performed a BLAST search
against the Protein Data Bank (PDB). Also signal peptides and
transmembrane regions were identified and removed, as these are
not included in the chemokine fold. Then, the cysteine content of
the remaining sequences was again evaluated to make sure that the
selected sequences would contain at least 2 cysteine residues (for
details see Materials and Methods section 2). This pre-filtering
resulted in a total of 2,141 uncharacterized sequences (Figure 1,
step 2).
3D fold family profiling. Thereafter, we generated a 3D
descriptor of the architecture of the chemokine fold family (IL8-
like) by using available information on 270 experimentally known
chemokine structures (Chemokine fold library). We performed
automatic 3D profiling on the pre-filtered 2,141 uncharacterized
sequences by carrying out threading calculations with ProHit
(ProCeryon Biosciences, ProHit Professional V 2.2.2) [25,26]
using the Chemokine fold library combined with an automatic
scaffold-based mapping of disulfide bonds (for details see
‘‘Chemokine 3D fold descriptor’’ and ‘‘Automatic scaffold-based
disulphide mapping’’ in Materials and Methods section 3).
Applying our scoring and ranking criteria, we selected: i) high
scoring sequences best fitting into the chemokine fold, and ii)
sequences that could potentially form disulfide bonds into the
Figure 1. Overview of our methodology. Uncharacterized human
proteins are extracted from the UniProt Knowledgebase. Steps 1–4 are
fully automated. The number of proteins that remain after each filter
step is summarized on the right.
doi:10.1371/journal.pone.0036151.g001
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fold. This automatic 3D protein fold family profiling resulted on
a total of 290 human protein sequences, until now
uncharacterized, that could potentially fold into a functional
IL8-like chemokine framework.
3D profiling across fold space. Next, we performed a 3D
profiling across fold space to investigate whether the best scoring of
the 290 filtered uncharacterized sequences would best fit into
a chemokine-like structure when compared to all other possible
structures in the fold universe. For this, we performed threading
control experiments across the currently available protein fold
space with our 70 top scoring sequences as query. A fold library
containing ,24,000 templates representing all the three-
dimensional structures currently available in the PDB (named
hereafter pdb95 fold library) was used for these purposes. Each of the
70 query sequences was analysed for folding preferences across
fold space. After applying our scoring and ranking criteria to the
results obtained, those query sequences with a chemokine
structure in the top 1 or 2 hits were automatically selected (for
details see Materials and Methods section 4). This resulted in
a total of 14 until now uncharacterized human protein sequences
that showed a stronger preference to fold into a functional
chemokine-like structure than into any other protein architecture
known up to date, and therefore with a strong potential to be
possible remote structural homologs of the IL8-like chemokine fold
family.
Our fully automated 3D profile-based methodology allowed us
to screen several thousands of so far uncharacterized human
protein sequences to discover a few candidates, which fit our 3D
chemokine fold family profile with high confidence. Further
detailed analysis of these 14 high confidence protein sequences was
performed in order to investigate their discovered strong structural
resemblance to the IL8-like chemokine fold and to substantiate
further structure-based functional predictions. The results ob-
tained in this 3D profiling across fold space for the best two
candidates (B42 and N73) are described in detail in the following
sections.
Discovery of Two Putative Remote Homologs of the IL8-
like Chemokine Fold
Each of the 14 automatically selected protein sequences was
separately examined for further characterization. Although the
sequences of our initial dataset were selected because of being
labelled as ‘‘unknown’’, ‘‘hypothetical’’ etc. in the UniProt
Knowledgebase (Materials and Methods section 1), we checked
for available information that could support or exclude their
annotation as potential novel chemokines. For this purpose we
used the InterPro database [27], which integrates predictive
models or signatures representing protein domains, families and
functional sites from diverse source databases (Materials and
methods section 5). Based on the InterPro signatures for each of
these 14 query sequences, we discarded four of them because they
refuted a chemokine-like fold: two were listed as transmembrane,
one as nucleotide-binding, and another one as a zinc-finger
protein. The high confidence sequence-to-structure alignments
obtained from our threading calculations with the pdb95 fold library
(i.e. chemokine fold in the top 1 or 2 hits; see above) were used to
generate atomic 3D models of each of the resulting 10 query
protein sequences using their corresponding top 1 or 2 ranking
chemokine fold as structural template (see Materials and Methods
section 6 and Table S2). The obtained 3D models were energy
minimized by molecular dynamics and, upon analysis of the results
(for details see ‘‘Analysis of models in Materials and Methods
section 6), six models were discarded because they did not show
the compact packing expected for a properly folded structure (data
not shown).
As a quality control and in order to compare the remaining four
3D models, (proteins G19, L32, B42 and N73; see Table 1 and
Table S2) with models of known chemokine structures, we built as
reference 3D models of the proteins vMIP-I and vMIP-II used as
templates to model our query proteins, and a model of the remote
member of the chemokine family CXCL17 [12] (see ‘‘Reference
models’’ in Materials and Methods section 6). These control
models were refined with the same MD protocol applied to the
query protein models. After evaluation of the MD results using the
control models as reference and taking into account overall
structure, packing of the protein core and contact residue
energetics (see ‘‘Analysis of models’’ in Materials and Methods
section 6), the models of proteins G19 and L32 were considered of
low quality because they did not show agreement with their
respective reference models (data not shown). The models of
proteins B42 and N73 showed good quality in agreement with
their respective controls, and were therefore considered as high
confidence predictions of chemokine-like structures. Based on our
results we hence predicted proteins B42 and N73 to be high
confidence structural homologs of the chemokine fold family.
The results obtained in the steps explained above (steps 1. to 6.
in methods) for proteins B42, N73, G19, L32 are summarized in
Table 1 and compared with those obtained for reference
chemokine CXCL17. Their corresponding genes were analysed
in detail for conservation across different species. In addition, we
checked exon organization, chromosomal location and proximity
to known chemokine genes, presence of a PolyA sites and Polyadq,
transcription factor binding sites of chemokine regulators and gene
expression profiles. Their protein sequences were analysed for
glycosylation sites and subcellular localization (for details see
section 7 in Materials and Methods). The analysis of protein
secretion and localization, number of exons, intron phase and
chromosomal location for these proteins is also summarized in
Table 1. Similar to CXCL17, the B42 and N73 proteins are
predicted to be secreted. In contrast, the obtained subcellular
localization predictions for G19 and L32 were contradictive.
Chemokine genes typically consist of 3–4 exons [28], which
coincides with what we observe for the B42 and N73 genes. The
results obtained for the discovery of B42 and N73 as putative new
human chemokines and their further characterization are de-
scribed in detail in the following sections.
Characterization of Chemokine-like Protein B42
B42 (UniProt: Q1T7F1) is 81 amino acids long and contains 6
cysteine residues. By using standard sequence-based methods
(BLAST and InterPro; see Materials and Methods for details), we
found no significant sequence homology of B42 to any previously
characterized protein. B42 was submitted to UniProt/TrEMBL
together with four zinc finger proteins (Q76KX8, Q1T7F5,
Q76KX9, Q1T7F6). The B42 gene was first automatically labeled
as zinc finger protein ZNF528 in Ensembl (release 54) because its
protein coding region was located within the untranslated region
(intron) of the Kruppel-like zinc finger gene ZNF528. The
translated B42 protein does not share sequence identity to any
characterized zinc finger protein, however, many zinc finger genes
are located in close proximity to the B42 gene on the chromosome.
Since Ensembl release 55, it was renamed to ZNF578, which,
according to the Ensembl annotation, does not code for a protein,
as it is labeled as ‘processed transcript’. The gene annotation of the
human B42 gene produced by the automatic Ensembl genebuild
prediction method did not detect the B42 gene in more recent
Ensembl releases (62 and higher) for reasons not specified on their
3D Profile-Based Discovery of Human Chemokines
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sequence of previous versions. Interestingly, the orthologous
chimpanzee and orangutan genes of B42 are still annotated as
novel protein coding genes in the current Ensembl release 64.
Fitting of the B42 sequence into the 3D chemokine-like
fold profile. Table 2 shows the best five hits resulting of
threading the B42 protein sequence against the Chemokine fold
library, which includes all currently available structural information
about the chemokine fold. The top two ranking alignments are
found with Kaposi’s sarcoma-associated herpesvirus encoded
vMIP-I and vMIP-II, which share 24.2% and 26.2% sequence
identity with B42, respectively. vMIP-I and vMIP-II are viral
chemokines known to block HIV entry through the chemokine
receptors CCR3 and CCR5 [29,30] and, in addition, vMIP-II is
able to block CXCR4. Likewise, the chemokine CCL3, found as
best scoring human chemokine (rank 3), is reported to block HIV
infection through the CCR5 receptor [31] as well as the truncated
version of CCL14 [9–74] (rank 4) and the human chemokine
CCL5 (rank 5) [32]. Interestingly, all high scoring templates for
B42 share the ability of binding to the chemokine receptor CCR5.
Besides the anti-HIV function, various different functions have
been reported for these template proteins, such as promotion of
angiogenesis [29] for vMIP-I and vMIP-II. For CCL5, induction
or inhibition of chemotaxis, proliferation [17] and induction of
apoptosis at high concentrations [18] have been reported.
Fitting of the B42 sequence into the chemokine-like fold
across fold space. Noteworthy, when B42 is threaded against
the pdb95 fold library, which contains representatives of all protein
folds currently available in the PDB, the IL8-like chemokine fold
appears as the top number one hit with the template v-MIP-I
(Table 3). With the alignment of the B42 sequence into the v-MIP-
I template structure, we could observe the possibility of formation
of three disulfide bonds in B42. Besides, the other top four hits
were considered false positives based on our filtering criteria based
on secondary structure and gap content, and fold coverage (see
Materials and Methods section 4 for details). These results were
strongly indicative of the protein B42 being a possible remote
structural homolog of the IL8-like chemokine fold.
Modeling B42 into a functional IL8-like chemokine
structure. The top threading hit vMIP-I (PDBId: 1ZXT,
resolution: 1.7 A ˚; Table 3) was used as template to model B42
as an IL8-like chemokine structure (Figure 2 A, B). Although B42
and vMIP-I share low sequence identity (24.2%), once B42 is
modelled into the chemokine-like scaffold, it can be seen that
structurally relevant amino acids forming the core of the fold are
well conserved in 3D. B42 presents a small insertion of 7 residues
between the third beta strand (b3) and the C-terminal alpha helix
with respect to v-MIP-I, and it has a longer C-terminus, which
includes a cysteine residue. The six cysteines contained in B42 are
coming together in 3D to form disulfides, which interestingly are
in non-canonical sequence and structure positions seen in known
chemokines. The three disulfide bonds predicted in B42 can be
seen in Figure 2B (cysteines C7 and C72, C8 and C29, C11 and
C45), which shows the vMIP-I template structure in comparison
with the 3D model of B42. Interestingly, our posterior mass
spectrometry experiments with the B42 protein showed
a monoisotopic mass of 8,931.2085 Da, which is indicative of
a yield of 3 intra-molecular disulfide bonds in the B42 protein (see
‘‘Experimental characterization of B42’’ below). These
experimental results further support our model and hypothesis
that B42 may fold into a functional IL8-like chemokine
architecture.
The 3D model of B42 was energy refined in a 10 ns molecular
dynamics (MD) simulation and analysed by using the 3D models of
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methods section 6). The CXCL17 chemokine has low sequence
identity to other known chemokines, and it was characterized by
threading and confirmed experimentally to have an IL8-like
chemokine fold [12]; therefore it constitutes a good reference for
comparison. In general, the B42 and vMIP-I models showed
similar behaviour during the MD trajectory (Figure S1 A).
Although B42 has a 7 amino acid small insertion and a flexible
tail of 8 amino acids at the C-terminus, which are not present in
the reference model, both, the coil and backbone RMSD curves of
B42 are in the same range as in the reference. Similar to the
reference model, the RMSD values of B42 converge over time,
indicating that the overall fold stays compact along the simulation.
These results are also comparable to the results obtained for our
reference model CXCL17 (Figure S1 C). These RMSD values
(0.2–0.3 nm) were assumed as an upper boundary for the
secondary structure RMSD values observed in the putative
chemokine models. These results further support the hypothesis
that the B42 sequence may adopt a compact IL8-like chemokine
fold.
In order to quantify the residue energetic contributions in the
B42 chemokine-like model, we calculated contact energies per
residue and compared them to those of the vMIP-I model. The
contact energy decomposition plot for B42 compared to vMIP-I
shows a general agreement in the energetic contributions of the
corresponding residues. In particular, it can be observed that the
secondary structure regions and the core of the protein present
a good agreement of the contact energies, indicating that the
packing of the core of B42 is comparable to the packing of the
vMIP-I template (Figure S2 A). We calculated the coefficient of
determination (R
2) from the contact energy pairs of the B42 model
and the reference model of vMIP-I, and we obtained an R
2 value
of 0.63 (Figure S3 A). We also did this analysis for the vMIP-I
using as reference a mutant of CXCL8 (PDBId: 1ICW), and we
obtained an R
2 value of 0.43 (Figure S3 C). We selected this
CXCL8 mutant as reference, because it has one disulfide bond at
a non-canonical position when compared to the rest of the
chemokine protein family, and it has low sequence identity (19%)
to vMIP-I. The R
2 value obtained for B42 is higher, which is
indicative of the good packing of the core in the B42 model
compared to known chemokines and gives high confidence to its
predicted structural resemblance towards the IL8-like chemokine
fold.
The possibility that B42 could be a lost remote homolog of the
chemokine protein family was further explored by searching for
the presence of chemokine-like features in its protein and gene
sequence.
B42 protein sequence and gene analysis. In the B42
protein sequence, we did not identify any signal peptide or
transmembrane region (see Materials and Methods section 2). At
present, one chemokine without signal peptide is known to be
transported to the nucleus [33] and so far no chemokine lacking
the signal peptide has been reported to be secreted. However,
there are some cytokines like IL-1a, IL-1b and IL18 that are
leaderless secreted by a non-classical secretion pathway [34]. For
this reason, we analysed possible leaderless secretion of the B42
protein with SecretomeP [35]. We obtained a high score, 0.8,
which indicates that leaderless secretion of B42 might be possible
Table 2. Fold recognition results for the top five hits obtained for B42 with the Chemokine fold library.
Rank Thx % ID CK Template PDB Chain pl fl UniProt Ragonist Rantagonist
1 45.6 24.2 vMIP-I 1ZXT A 62 69 Q98158_HHV8 CCR8, part. CCR part CCR5
2 45.1 26.2 vMIP-II 1CM9 B 65 67 VMI2_HHV8P CCR3 CCR5,1,2, CXC4,
XCR1, CX3CR1
3 38.5 21.0 MIP-1A 3FPU B 62 66 CCL3_HUMAN CCR1, CCR5 –
4 35.6 18.0 CCL14 2Q8R H 61 63 CCL14_HUMAN CCR1,3, CCR4 –
5 30.6 20.6 RANTES 2VXW A 63 69 CCL5_HUMAN CCR1,3, CCR5 –
Rank: rank of hit within all chemokine structures in the fold library; Thx: threading index; %ID: percentage of sequence identity between query and template; CK
Template: PDB template; PDB: template identifier in the Protein Data Bank; chain: template chain; pl: alignment path length; fl: template fold length; UniProt: UniProt
identifier; Ragonist: Chemokine receptors for which the template protein is an agonist; Rantagonist: Chemokine receptors for which the template protein is an
antagonist.
doi:10.1371/journal.pone.0036151.t002
Table 3. Fold recognition results for the five top fold hits obtained for B42 with the pdb95 fold library.
Rank Conf sse gap fcov Thx %ID SCOP %Cov Template PDB Chain pl fl UniProt Pfam
1H C ++ + 45.6 24.2 d.9.1.1 98 vMIP-I 1ZXT A 62 69 Q98158_HHV8 IL8
2F P + 2 + 39.4 21.4 g.3.7.2 100 ergtoxin 1PX9 A 42 42 KGX11_CENNO Toxin_17
3F P ++ + 34.2 21.9 a.60.1.2 100 Diacylglycerol kinase 3BQ7 D 73 68 DGKD_HUMAN SAM_2
4F P + 2232.7 16.1 c.2.1.1 72 L-Thr 3-dehydrogenase 2D8A A 81 348 TDH_PYRHO ADH_N
5F P ++ + 31.7 15.2 a.77.1.2 99 TNF-Receptor 1 1ICH A 79 87 TNR1A_HUMAN Death
Only best template per SCOP fold is shown. Rank: rank of hit within all structures in the fold library Conf: confidence level of prediction (HC, high confidence; FP, false
positive); sse: all secondary structure elements present in alignment; gap: gaps shorter than 10 amino acids; fcov: fold coverage based on ratio of fold length/path length
(fl/pl); Thx: threading index; %ID: percentage of sequence identity between query and template; SCOP: SCOP family identifier; %Cov: percentage of domain coverage;
Template: PDB template; PDB: template identifier in the Protein Data Bank, Chain: template chain; pl: alignment path length; fl: template fold length; UniProt: template
UniProt identifier; Pfam: Pfam description.
doi:10.1371/journal.pone.0036151.t003
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extracellular location for B42 with a very high confidence (31 out
of the maximal possible 32 nearest neighbours are extracellular
localized). We also analysed the B42 sequence with the ELM
server for possible glycosaminoglycans (GAG) interaction sites, as
it is known that GAG interaction is a common feature of
chemokines [37]. We identified one putative GAG attachment
site, RSGG, in residues 49–52. Our search for B42 orthologous
with the Ensembl’s automatic annotation pipeline (Release 54)
[38] identified one in chimpanzee and another one in oranguthan
(98% and 91% protein sequence identity to B42, respectively),
which are also still functionally uncharacterized (Figure 3C).
The B42 gene lies within the same chromosomal region
(19q13.41) as two other known chemokines (CXCL17 and
CCL25), which are found at 19q13.2. Similar to many known
chemokines, the B42 coding transcript originates from 3–4 exons.
Another common feature of chemokines is that the exon
boundaries have similar intron phases (position of the codon
within the intron). They have the intron phase 1 between exon 1
and 2, and phase 2 between exon 2 and 3 [39]. Similarly, the
protein coding region of B42 starts at the end of exon 2 and ends
with exon 3 presenting a phase 2 intron boundary between exon 2
and 3 (Table 1 and Figure S4 A). Furthermore, the promoter
region of B42 was analysed for transcription factor binding sites
known from other chemokines, and we found binding sites for NF-
IL6, NF-kappaB, AP1 (C-Jun) and INF-1 [40–46]. In addition, we
found the CK1 motif that was previously described as a chemokine
specific motif found in the chemokines MIP-1a and MIP-1b
(Table S3) [43].
In summary, the results obtained from our computational
analysis strongly support that B42 may adopt an IL8-like
chemokine fold as preferred from all known folds currently
Figure 2. Modelling of the B42 protein as an IL8-like chemokine. A) Sequence-to-structure alignment of B42 with its best scoring template
vMIP-I (PDBId: 1ZXT). The secondary structure of vMIP-I is indicated below (yellow arrows for b-strands, red cylinders for a-helices, and dark grey line
for coil regions; the light grey line indicates no atom coordinates for those residues in template). Cysteines are highlighted in boxes coloured (green,
red, and blue) according to their pairing in each protein sequence. B) The 3D model of B42 (left) is compared with the X-ray structure of vMIP-I (right)
used as template. Disulfide bonds are shown as orange sticks, and corresponding cysteines are labelled according to their pairing with the same
colour code as in panel A. C) Sequence alignment of human B42 with its orthologous proteins (Ensembl release 54). Cysteines are highlighted in black
boxes. The sequence identity between human and chimpanzee (Chimp_B42: ENSPTRG00000034188) is 98%, and 91% with oranguthan
(OranUthan_B42: ENSPPYG00000010339).
doi:10.1371/journal.pone.0036151.g002
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PLoS ONE | www.plosone.org 6 May 2012 | Volume 7 | Issue 5 | e36151Figure 3. Modelling of the N73 protein as an IL8-like chemokine. A) Sequence-to-structure alignment of the mature N73 (without signal
peptide) with its best scoring template vMIP-II (PDBId: 2FJ2). The secondary structure of vMIP-II is indicated below (yellow arrows for b-strands, red
cylinders for a-helices, and dark grey line for coil regions; the light grey line indicates no atom coordinates for those residues in template). Cysteines
are highlighted in boxes coloured (green, red, and blue) according to their pairing in each protein sequence. B) The 3D model of N73 (left) is
compared with the X-ray structure of vMIP-II (right) used as template. Disulfide bonds are shown as orange sticks, and corresponding cysteines are
labelled according to their pairing with the same colour code as in panel A. C) Sequence alignment of the human N73 precursor with its orthologous
proteins. Cysteines are highlighted in black boxes. Predicted N-glycosylation sites are shown in pink boxes, and the RGD motif in orange boxes. Under
the alignment, ‘s’ indicates location of signal peptide (SP), ‘*’ indicates location of low complexity region (LCR), ‘c’ indicates location of predicted
chemokine domain, ‘g’ indicates motif for glycosaminoglycan attachment at a serine residue, and ‘,’ indicates location of disordered region
predicted by GlobPlot. The sequence identity between human and gorilla (pre_N73_Gorilla: ENSGGOP00000010336) is 96%, and 45% with bushbaby
(pre_N73_Bushb: ENSOGAP00000012479).
doi:10.1371/journal.pone.0036151.g003
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B42 shows good packing and energetics comparable to other
experimentally known chemokine structures. In addition, in this
predicted 3D scaffold, B42 is able to form three disulfide bonds,
which are structural features known to be necessary for
chemokines to fold and function. The fact that these three
disulfide bonds are not conserved in 3D with respect to other
known structures of members of the chemokine family, and also
the low sequence similarity of B42 to known family members could
explain that B42 has escaped annotation by sequence-based
methods. Furthermore, the identification of functional chemokine-
like features in the B42 protein and gene sequence such as GAG
interaction site, number of exons, intron phase, chromosomal
proximity to known chemokines and similar transcription factor
binding sites, all together add confidence to our structural
prediction of B42 being a possible remote homolog of the IL8-
like chemokine family. In terms of its putative function as
a chemokine, a remarkable observation is that B42 is a primate
specific protein, and that all the five best ‘high confidence’
template structures obtained in our threading experiments (vMIP-
I, vMIP-II CCL3, CCL14, CCL5) are reported to have anti-HIV
functions. All in all, our findings make us hypothesize that B42
could be a putative chemokine that could inhibit HIV infection,
which constitutes a very interesting testable hypothesis.
Characterization of Chemokine-like Protein N73
N73 (UniProt: Q71RG6) is 208 amino acids long and contains
12 cysteine residues. Sequence analysis using standard sequence-
based methods (see Materials and Methods) did not identify any
statistically significant sequence homology of N73 to any pre-
viously characterized protein. N73 was first identified as a gene
related to cancer development and progression in a large-scale
cDNA transfection screening. The transfection with N73 cDNA
resulted in inhibition of growth in the Hepatoma 7721 cell line and
stimulation of growth in the fibroblast cell line NIH3T3 [47].
The same computational analysis performed for B42 explained
above was also carried out for the N73 protein (for details see
Supporting Information Text S1 section II). The fitting obtained
for the N73 sequence into the chemokine fold using both the
Chemokine fold library and the pdb95 fold library was, like in B42,
strongly indicative of the protein N73 being a possible remote
structural homolog of the IL8-like chemokine family (Table S4
and S5). The top threading hit vMIP-II (PDBId: 2FJ2; 2.3 A ˚ and
23.2% sequence identity) was used as structural template to model
N73 as an IL8-like chemokine. Compatible with the proposed
chemokine fold, in this structural framework there are two
possibilities of disulfide bond formation (Figure 3 A and B). The
MD optimization of our N73 chemokine-like model, its compar-
ison with reference models of vMIP-II and CXCL1, and the
contact energy analysis performed were indicative of a good
packing of the core in the predicted 3D scaffold (Supporting
Information Text S1 section II, Figure S2 B, Figure S3 B).
The analysis of the N73 sequence uncovered several chemokine-
like properties such as the presence of a signal peptide for
secretion, a GAG attachment site as well as an N-linked
glycosylation site (Figure 3C; see Supporting Information Text
S1 II for details), which are also known from other chemokines like
CCL2 [48]. We also found transcription factor binding sites
known from other chemokines in its promoter region (Supporting
Information Text S1 II and Table S6). Interestingly, N73 was
previously identified to be involved in cancer development and
progression, which could be caused by the RGD-integrin binding
motif in its sequence (Figure 3C). By integrin interaction with this
motif, N73 might acquire anti-angiogenic function. On the other
hand, the analysis of orthologous showed that, similar to B42, N73
is a primate specific protein (Figure 3C). The N73 gene (Gene ID:
ENSG00000184334 in Ensembl release 61) comprises 3 exons like
many other chemokines; however, the protein coding region lies
only on the first one. The open reading frame is located on
chromosome 8q24.3. At present, no other chemokines are known
to be located on this chromosome. Close to the N73 gene, an
orphan G protein coupled receptor (GPR20) is found (Figure S4
B). The annotation of the human N73 gene produced by the
automatic Ensembl genebuild prediction method did not detect the
N73 gene in more recent Ensembl releases (62 and higher) for
reasons not specified on their website, although the genomic
sequence is identical to the sequence of previous versions.
Interestingly, the orthologous gorilla and bushbaby genes of N73
are still annotated as novel protein coding genes in the current
Ensembl release 64.
In summary, the results obtained in our computational analysis
support our prediction that N73 may adopt a functional IL8-like
chemokine fold. Furthermore, the fact that N73 resembles the
structures of the chemokines vMIP-II and vMIP-I that are known
to have anti-HIV functions suggests that also N73 might share
these properties, which constitutes a very interesting testable
hypothesis.
Experimental Characterization of B42
In order to corroborate our predictions, we carried out gene
expression analysis, protein expression studies, and protein
structure investigations by means of Circular Dichroism (CD),
Fourier transform infrared spectroscopy (FTIR) and Mass
Spectrometry (MS).
Gene expression analysis. Gene expression studies utilizing
cDNA isolated from different tissues and subsequent sequencing of
the PCR products identified two B42 isoforms. Only isoform A is
protein coding and expressed in placenta, heart, lung, liver,
pancreas, skeletal muscle and weakly in brain (Figure 4A). Isoform
B exhibits a stop codon within the additional longer exon 3
sequence encoding a short peptide of 9 residues, which is
expressed mainly in kidney, placenta, pancreas, liver and weakly
in lung and muscle (Figure 4B). Bone marrow cDNA was also
tested but no B42 expression was found (data not shown).
In vivo protein expression and localization. A transgenic
HeLa cell line was generated carrying the LAP-tagged B42 gene in
a bacterial artificial chromosome (see Materials and Methods
section 8 for details). The expression of the transgene was
confirmed by Westernblot (Figure 5A) showing that B42 is
expressed and translated into protein. Our results confirm the
existence of the translated protein B42 and thus prove wrong its
previous Ensembl labeling as a ‘processed transcript’ (rel. 55–61)
and the complete removal of the B42 gene in more recent Ensembl
releases (62 and higher) (see Figure S4 A).
Immunoflourescent staining and imaging of the transgenic cell
line showed positive cells at a low percentage (2%). The
localization of B42 is ubiquitous, mainly cytoplasmic (Figure 5B,
C) and does not change over the different cell cycle phases (data
not shown). No indication for secretion of B42 in the transgenic
cell line was observed. However, a missing additional stimulus or
hindrance by the GFP-tag could explain that B42 does not seem to
be secreted in our analysis. Although not observed in our
experiments, currently available predictors support the hypothesis
that B42 could be leaderless secreted. It could also be possible that
B42 may act like PESKY, a non-secreted mouse isoform of the
chemokine CCL27, which is able to modulate transcription in the
nucleus [33].
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Spectrometry. The in vitro expressed B42 protein (glycine-
adenine-B42) was analyzed by SDS-page gel electrophoresis to
verify B42 protein recovery (Figure 6). The same construct was
analyzed by Mass Spectrometry. The result of the experimental
deconvoluted mass spectrum was then compared to the theoretical
isotopic distribution for glycine-adenine-B42 assuming 3 disulfide
bonds based on our 3D models. The experimental value
Figure 4. Expression and gene structure of the B42 isoforms. A) Expression of two B42 isoforms in human tissues (expected size for isoform A:
272 bp). B) Sequencing results of the two different B42 isoforms. Isoform A codes for the full length B42 protein, whereas Isoform B contains a stop
codon after 9 residues.
doi:10.1371/journal.pone.0036151.g004
Figure 5. Protein localization results of B42. A) Westernblot analysis of the C-terminal GFP-tagged B42 transgenic cell pool using an antibody to
GFP. A weak band of the expected size 39.8 kDa (GFP-tag: 31 kDa+B42 8.8 kDa) was detected (marked with *). B) Immunoflourescent staining of the
transgenic cell line. Two positive and two negative cells of the cell pool are shown. Localization of the C-terminal GFP-tagged B42 protein is mainly in
the cytoplasm of HeLa cells: GFP - green, alpha-tubulin - red, DNA (DAPI) – blue. C) Only GFP-signal of B is shown in grey scale.
doi:10.1371/journal.pone.0036151.g005
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expected theoretical value (8,931.1423 Da). Accordingly, the
experimental monoisotropic mass of B42 indicates that all 6
cysteines are oxidized and thus involved in the formation of three
disulfide bonds as predicted.
Analysis of secondary structure content by CD and
FTIR. The fractions of secondary structure elements
calculated for B42 from the Circular Dichroism (CD) and
Fourier transform infrared (FTIR) spectroscopy spectra are in
agreement with the theoretical fractions calculated for our
chemokine-like 3D model (Table 4), which confirms our
structural predictions. The comparison of the CD spectra of
B42 with the spectra of the chemokine vMIP-II shows a similar
pattern suggesting similar secondary structure content in both
proteins (Figure 7). The small difference observed in the content
of beta sheets might be due to: i) an underestimation of the
secondary structure content of our model (i.e. extended regions
not defined as beta strands), and ii) the possibility of oligomer
formation, which we do not consider when calculating the
percentages of secondary structure elements for our chemokine-
like 3D model of B42, as B42 is modelled as monomer.
Oligomerisation is a common feature of chemokines. In
particular, vMIP-I and vMIP-II are known to dimerize by
forming inter-chain beta sheets between their N-termini [49]
and the same dimerization mode was also observed for the
chemokines CCL3, CCL5 and CCL14 [49] found as best
ranking human templates for B42 (Table 2).
In summary, we have shown that the B42 gene is expressed in
several human tissues, and encodes an in vivo translated folded
protein. This contrasts with the fact that the B42 gene product was
previously labelled as a ‘processed transcript’ in Ensembl and as
‘retired’ in more recent releases. The experimentally measured
secondary structure content of the B42 protein is in agreement
with that calculated for our chemokine-like model of B42 and the
one reported for vMIP-I and other chemokines. Furthermore,
mass spectrometry experiments corroborate the existence of three
disulfide bonds, which our model predicts to be determining the
folding of the IL8-like chemokine architecture and that could be
indicative of a putative chemokine function for B42. All in all, our
experimental results further support our prediction of B42
adopting an IL8-like chemokine fold, and they substantiate our
structure-based functional hypothesis, which proposes B42 as
a putative novel human chemokine.
Conclusions
We have developed a new computational approach for
automatic proteome-wide identification of novel chemokines based
on three-dimensional properties of this protein family. In this 3D
profile-based methodology, we combine fold recognition methods
with automatic scaffold-based disulfide mapping to detect
structural and functional patterns in 3D space indicative of
a preference for a functional IL8-like chemokine fold. We apply
our methodology to several thousands of so far uncharacterized
human proteins to identify potential remote homologs of the
chemokine protein family that may have not yet been discovered
due to their low or inexistent sequence similarity to already
characterized family members, and possibly also due to their non-
canonical cysteine patterns in sequence and in 3D. We describe
the discovery of two new proteins, B42 and N73, which we predict
with high confidence to resemble the IL8-like chemokine fold of
vMIP-I and vMIP-II, despite their respective low sequence
similarities to known members of the chemokine protein family.
Based on our computational results and in the obtained
experimental supporting evidence, we propose the B42 protein
to be a new structural member of the IL8-like chemokine fold
family and possibly a new human chemokine. Based on the
observation that B42 and N73 are primate specific proteins and
because of their structural resemblances towards known anti-HIV
chemokines, we postulate the possibility that both proteins might
have an HIV inhibitory function. Furthermore, based on the
sequence features observed for N73, we hypothesize that N73
might be able to promote tumor necrosis in cancer, like known
angiostatic chemokines. Further experimental analyses will be
necessary to support these hypotheses.
Our findings are relevant for the signature of the chemokine
family, as it gets enriched with the discovery of each new family
member, and it may then help to identify new members. Each of
these discoveries may shed light on the molecular mechanisms of
the functions of the chemokine protein family, an understanding
essential for the development of treatments for pathological
processes where these proteins are involved. Besides, the 3D
family profile-based methodology presented here and the results
obtained denote the significance of structure-based methods as
complementary approaches to current sequence-based approaches
for genome-wide detection of similarities among proteins at very
low or even non-existent levels. The 3D scaffold-based profile
concept applied here could be easily extended to other disulfide-
containing protein folds and, furthermore, to any other fold family
for which structure-to-function markers may be described and
automatically screened in 3D. More than 500 of the currently
known protein folds contain disulfide bonds, and some are
associated to inflammatory responses, angiogenesis or cancer
processes, which certainly represent very interesting targets for
future discovery. Thus, the concept of our methodology has
important implications for helping in the discovery of remote
homologs of protein families with interesting properties for
medicine and technology developments. All in all, our approach
may be of help in functional genomics efforts and support protein
annotation attempts for proteins that fall into the twilight-zone of
the protein sequence-to-structure universe.
Figure 6. Deconvoluted mass spectrum of B42. Upper panel:
Deconvolution of experimental spectrum with monoisotopic peak
labelled. Inlay: SDS-page gel electrophoresis results to check B42
protein recovery. Lower panel: Theoretical isotopic distribution for [GA-
B42] assuming 3 disulfide bonds, with monoisotopic peak labelled.
doi:10.1371/journal.pone.0036151.g006
3D Profile-Based Discovery of Human Chemokines
PLoS ONE | www.plosone.org 10 May 2012 | Volume 7 | Issue 5 | e36151Materials and Methods
1) Sequence Data Extraction
The sequence dataset used in our study was extracted from the
UniProt Knowledgebase (Release 14.9) consisting of UniProtKB/
Swiss-Prot Release 56.9 and UniProtKB/TrEMBL Release 39.9.
All human protein sequences labelled as ‘‘unknown’’, ‘‘orf’’,
‘‘hypothetical’’, ‘‘uncharacterized’’ or ‘‘putative’’ that contained at least
two cysteine residues in their sequence were selected for our
studies.
2) Automated Pre-filtering
Structural annotation check. BLAST against the PDB was
used to detect query sequences or parts of them that could be
already structurally characterized. Alignments longer than 50
residues with an e-value #0.0005 and with sequence similarity
.30% were considered annotated and were, therefore, discarded
for further analysis.
Signal peptides. Signal peptides (SP) were predicted in the
query sequences using the consensus of two different prediction
methods: PrediSi [50] and SigPfam [51]. We tested both methods
using default parameters and a dataset of 24 protein sequences.
Based on the annotated positions of the signal peptides in the test
dataset, we used the scores calculated by each method to assign
confidence groups to combine the results of both methods and thus
remove those regions predicted as signal peptides with high
confidence (for details see ‘‘Consensus signal peptide prediction’’
in Supporting Materials and Methods).
Transmembrane regions. We predicted transmembrane
(TM) regions in the query sequences using the consensus of two
different prediction methods: TMHMM [52] and Memsat [53].
As the average length of a TM helix is known to be 21 residues,
and 94% of all TM segments have a length between 17 and 25
residues [54], we assigned confidence groups for the consensus
prediction based on the predicted length of the TM region.
According to the TM segment length, we assigned confidence
groups for each predicted membrane segment. For high and
medium confidence predictions, the predicted TM region was
removed from the query sequence (for details see ‘‘Consensus
transmembrane prediction’’ in Supporting Materials and
Methods).
Cysteine content and sequence length. The cysteine
content of the remaining sequences was evaluated, and only
those sequences with two or more cysteine residues and
a minimum sequence length of 55 amino acids were selected for
further analysis.
Table 4. Predicted and experimentally determined secondary structure content of B42.
% Predicted from model % Measured by CD % Measured by FTIR
a helical 10 15 14
b strand 17 27 45
Turn/b turn 20 19 21
Unordered 53 35 19
Secondary structure fractions (in percentage and number of amino acids) calculated for the 3D model of B42 and compared with the experimentally determined
fractions obtained by Circular dichroism (CD) and Fourier transform infrared (FTIR) spectroscopy.
doi:10.1371/journal.pone.0036151.t004
Figure 7. Circular dichroism (CD) spectra of vMIP-II and B42. The CD spectrum of chemokine vMIP-II taken from literature [68] is shown (left)
in comparison to the spectrum measured for B42 (right).
doi:10.1371/journal.pone.0036151.g007
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Chemokine 3D fold descriptor. As three-dimensional
descriptor of the IL8-like chemokine architecture, a fold library
was built (Chemokine fold library) that contained as templates all
structures available from the Brookhaven Protein Data Bank
(PDB) that are classified as IL8-like chemokine fold in SCOP
(SCOP: d.9). This library consisted of 270 structural templates of
chemokines.
For the pre-filtered query sequences, sequence-to-structure
alignments and 3D models were obtained using the fold
recognition algorithm ProHit (ProCeryon Biosciences, ProHit
Professional V 2.2.2) [25,26]. ProHit was used with parameters
as previously described for gap handling, scoring, and
evaluation of the alignments [12]. The final overall threading
ranking was calculated based on the ProHit Threading index
(Thx), which is a combination of sequence similarity, residue-
residue (z_pair) and residue-solvent (z_surf) interaction z-scores
normalized by the query sequence length. A cutoff of 25.3 for
the threading index was considered as representative cutoff for
the chemokine family, as it was obtained by threading the
remote member of the chemokine family CXCL17 [12] (Table
S7). The percentage of amino acid sequence identity (%ID)
between query and template sequences as well as the percentage
of SCOP domain coverage (%Cov) of the query sequence onto
the template structure were calculated. To exclude false
positives (FP), we used the ratio between the template fold
length (fl) and the number of aligned residues in the sequence-
structure alignment (path length: pl) as previously described [12]
to reject those sequence-structure alignments not covering the
full length of a given template fold were rejected. Hits with
values 0.6#fl/pl#1.3 were considered to be of high confidence
(HC), and all other were considered to be false positives (FP). In
addition, high confidence hits should have all secondary
structure elements of the template covered by the query
sequence, and the sequence-to-structure alignment should not
contain gaps longer than 10 amino acids. Alignments not
fulfilling these criteria were rejected.
Automatic scaffold-based disulfide mapping. All possible
cysteine pairs in the query proteins were automatically checked for
disulfide bond formation possibilities based on the obtained query-
sequence to template-structure alignment for each HC threading
hit. The template structures were automatically mapped for
possibilities of disulfide bond formation in positions where the
query sequence had cysteine residues using the following criteria:
i) d(Ca1, Ca2)#10 A ˚ and d(Cb1, Cb2)#9A ˚: The distance between the
Ca atoms of two cysteines should be #10 A ˚ and between their Cb
atoms #9A ˚.
ii) d(Cb1, Cb2)2d(Ca1, Ca2)#1A ˚: The distance between the Cb
atoms should not be much bigger than the distance between the
Ca atoms (i.e. the side chains should not point in opposite
directions from each other; which would not enable disulfide bond
formation).
iii) Two cysteines should be 3 amino acids apart in the protein
sequence to be able to form a disulfide bond.
A disulfide bond in the query protein was considered to be
possible when all these criteria were fulfilled. In cases where
cysteines of the query sequence were aligned to a gap or an
unresolved residue in the template, the coordinates of the closest
left and right sequence neighbour in the template were used to
measure possible pairwise cysteine distances.
4) 3D Profile Search Across Fold Space
For the control threading experiments, a fold library containing
all structures in the PDB filtered at 95% sequence identity was
used in order to avoid redundancy and to account for all
representative 3D architectures (pdb95 fold library). This library
consisted of 23,833 structures. The threading calculations and
ranking were performed as described above for the chemokine-like
3D fold descriptor. The following selection criteria were applied to
decide on high confidence chemokine-like candidates:
Fold and SCOP domain coverage. As described above for
the chemokine-like 3D fold descriptor, only sequence-to-structure
alignments corresponding to fully covered template folds were
considered. For this, and as previously reported [12], hits with
values 0.6#fl/pl#1.3 were considered to be of high confidence,
and all other were considered to be false positives (see section 3
above for details). The same criteria as explained above were used
for allowing gaps in the query-to-template alignment and discard
false positive hits.
The structural templates in the pdb95 fold library may contain
more than one SCOP domain in the same PDB chain; we
therefore used an additional criterion to discard those SCOP
domains in the results list that were not fully covered: the SCOP
domain coverage (%Cov). All folds with an SCOP domain
coverage lower than 70% were considered incomplete hits and
discarded. The top 20 SCOP domains were considered, and only
those query sequences that had the chemokine fold ranked as first
or second high confidence hit after applying the fold and SCOP
domain coverage filter were taken for further analysis.
5) InterPro Analysis
The InterPro database (http://www.ebi.ac.uk/interpro/) was
used to look for signatures in the selected sequences that could
contradict our predictions. InterPro integrates predictive models
or signatures representing protein domains, families and functional
sites from diverse source databases such as Gene3D, PANTHER,
Pfam, PIRSF, PRINTS, ProDom, PROSITE, SMART, SUPER-
FAMILY and TIGRFAMs [27].
6) 3D Model Building and Analysis
Comparative modelling and refinement. The
MODELLER package [55] was used to generate 3D models of
the query proteins based on the sequence-to-structure alignments
obtained from threading calculations with the pdb95 fold library
(Table S2). The MOE2008.10 program (Chemical Computing
Group, Quebec, Canada) was used to connect unbound cysteines
where disulfide bond formation was predicted and to adjust side
chain rotamers when needed. The resulting models were energy
minimized the with the Amber99 force field [56] in MOE. Good
models were selected based on two criteria: proper formation of
secondary structure regions with respect to the template structures
and good disposition of inserted regions. Models were refined by
applying 10 ns molecular dynamics (MD) simulations, which were
performed using GROMACS 3.3 [57,58] with the G53a6 force
field (GROMOS96.1) [59] using a previously described protocol
[60]. The refined models were graphically analysed using VMD
[61], MOE2008.10 and Discovery Studio 1.7.
Reference models. The 3D models of the template proteins
vMIP-I and vMIP-II were built by using the backbone of their
experimental structures (PDBId: 1ZXT and 2FJ2, respectively)
and adding the corresponding side chains with MODELLER [55].
The model of CXCL17 was generated using MODELLER and
the X-ray structure of CCL17 as template, as it is the best
compatible chemokine template structure currently available in
PDB (PDBId: 1NR4; 1.72 A ˚ and 21.4% sequence identity) (see
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described above.
Analysis of models. The refined models of the putative
chemokines were evaluated by: 1) Analysis of their RMSD plot
through the MD simulation, 2) comparison of the RMSD plots of
the simulation of the putative chemokine models with the RMSD
plot of the corresponding reference models (vMIP-I and vMIP-II,
respectively, as well as CXCL17), and 3) graphical analysis of the
overall structure after the simulation and 4) comparison of the
packing of the protein core by analysis of the energetic
contributions of each residue in the templates with the
corresponding residue in the putative chemokine models (contact
energy correlation; see below).
Contact energy calculation and correlation
analysis. The contact energies per residue of coordinate
snapshots taken from the MD simulation were calculated using
the contact energy function built in MOE2008.10 and as
previously reported [60]. To analyse the correlation of the per
residue contact energies between reference templates and
chemokine-like models, we calculated a structure-based sequence
alignment for each chemokine model with its respective reference
template using the structure alignment algorithm ProSup in
ProHit. This alignment was then used to calculate the coefficient
of determination (R
2) for the contact energy pairs of structurally
corresponding residues in the alignment (gaps were not
considered). To estimate the order of correlation that can be
expected from a known chemokine, the same analysis was done for
the reference chemokines with the X-ray structure of a CXCL8
mutant (PDBId: 1ICW).
7) Detailed Protein and Gene Analysis
Orthologous proteins were identified using the Ensembl
automatic annotation pipeline (Release 58) [38] and analysed
with the Jalview 2.4 alignment viewer {Waterhouse, 2009 #129}.
Exon organization, chromosomal location and proximity to
known chemokine genes, presence of a PolyA site (using Ensembl,
Polyah.pl (softberry) and Polyadq [62]), transcription factor
binding sites of chemokine regulators [40–45] and gene expression
profiles (GeneNote expression study [63]) were checked. Protein
sequences were analyzed for eukaryotic linear motifs and
glycosylation sites using the functional site detection server ELM
[64] with the ‘extracellular’ filter. Subcellular localization was
predicted with WoLF PSORT [36]. In case no signal peptide was
present leaderless secretion was checked using SecretomeP [35].
8) Experimental Methods
Gene expression analysis (PCR). The mRNA expression of
B42 was analyzed by PCR with human cDNA templates from
eight different tissues (heart, brain, placenta, lung, liver, skeletal
muscle, kidney, pancreas) using Human MTC Panel I (Clontech,
Catalogue No. 636742, LOT No. 8082935A) with forward and
reverse primers 59-CCTAAGGAAGAAGCCTAGAAGAGG-39
and 59-CAGGCAGTTGTGCACATTAAG-39, respectively
(annealing temperature 58uC).
Generation of a BAC transgenic HeLa cell line and tag-
based protein localization. Transgenic HeLa cell lines [65]
were generated carrying the tagged gene of interest in a BAC
(bacterial artificial chromosome) using the methodology described
by Poser et al [65].
Protein expression and purification. The gene encoding
the mature B42 protein was synthesized and cloned in an
expression plasmid pETMM-60. The expression and purification
was done in E. coli Origami B cells (Novagen) (for disulfide bonds
formation in cytoplasm because of a glutathione S transferase
mutation) as described by Magistrelli [66] using a His-tagged
NusA fusion protein as to make the putative chemokine as fusion
partner soluble. The putative chemokine was cleaved from NusA
at the TEV cleavage site with TEV protease at a 1:100
concentration overnight at 18uC. After cleavage the chemokine
construct keeps a GA-addition of the cleavage site at the N-
terminus. The B42 protein was then purified and afterwards
concentrated. The expression and purification of the right
construct was confirmed by SDS-Page and mass spectrometry.
Validation of disulfide bond formation by Mass
Spectrometry. Mass spectrometry was used to validate the
formation of disulfide bonds. Experiments were done with
a protein concentration of 28.29 mM/mL in 16PBS and at a pH
of 7.3. Desalting and concentration was performed with a C-18-
mZipTip (Millipore, Billerica, USA) supplemented with Poros
Oligo R3 (C-18 reversed phase, Applied Biosystems Germany,
Darmstadt, Germany) prepared in-house. The sample was
acidified by addition of 2 ml 30% formic acid to 18 ml protein
solution, washed three times with 5% methanol 0.1% formic acid
and eluted in 40% methanol 0.1% formic acid. Analysis of the
sample was carried out with on an Orbitrap XL mass spectrometer
(ThermoScientific, Bremen, Germany) by direct infusion with
a TriVersa Nanomate robot using 2.1 mm nozzle chips (Advion
BioSciences, Ithaca, USA). Data was acquired in profile mode at
a resolution of 60000 at 400 Th and automatic gain control was
enabled with a target value of 5*10 E5. Spectrum deconvolution
was performed with the XtractAll add-on to the Xcalibur software
suite (Thermo Scientific, Bremen, Germany).
Circular dichroism spectroscopy. For determination of
secondary structure fractions, Circular Dichroism measurements
were carried out in the far UV-range (190–260 nm) on a Jasco J-
815 Circular Dichroism Spectropolarimeter using cuvettes of
0.2 mm path length. The protein was used at a concentration of
28.3 mM/mL at 20uCi n1 6PBS, pH 7.3. The results were
averaged over ten repetitive scans at a scan rate of 1 nm/s.
Ellipticity was normalized to molarity using a mass of
8,931.2085 Da as determined by mass spectrometry. The
secondary structure content was calculated using CONTINLL
and SELCON3, both provided in the CDpro software package.
Fourier transform infrared spectroscopy. Fourier
transform infrared (FTIR) spectroscopy was used to obtain the
overall fractions and alpha helical and beta sheet secondary
structure elements in the measured protein. The amide I band was
decomposed into peaks with Peakfit and the percentage of
secondary structure elements was calculated using the factors
described by de Jongh et al [67].
Supporting Information
Figure S1 Results of MD simulations for chemokine-
like models of B42, N73, and the reference models of
vMIP-I, vMIP-II and CXCL17. A) RMSD along the MD
simulation of the chemokine-like B42 model (left) and vMIP-I
model (right). B) RMSD along the MD simulation of the
chemokine-like N73 model (left), and vMIP-II model (right). C)
RMSD along the MD simulation of the CXCL17 model. Black
lines correspond to backbone, margenta to secondary structure
elements, and blue to coil regions.
(TIF)
Figure S2 Contact energy decomposition plots. Contact
energies of the residues in the putative chemokine models are
compared to the corresponding residues in their template
structures (gaps are not considered). A) Comparison of contact
energies per residue for B42 and vMIP-I. B) Comparison of
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structure elements of the templates are indicated below as arrows
for b-strand and cylinders for a-helix.
(TIF)
Figure S3 Contact energy correlation analysis. Correla-
tion of contact energies pairs of the putative chemokine models of
B42 and N73 with their corresponding template reference models.
A) B42 model vs. reference model vMIP-I (R
2=0.63). B) N73
model vs. reference model vMIP-II (R
2=0.41). C) Reference
model vMIP-I vs. X-ray structure of CXCL8 mutant (R
2=0.43).
D) Reference model vMIP-II vs. X-ray structure of CXCL8
mutant (R
2=0.51).
(TIF)
Figure S4 Ensembl annotations of B42 and N73. A) B42.
Coding regions on exons are indicated by filled boxes. The open
reading frame is located on chromosome 19q13.41. 1) Ensembl
release 54, 2) Ensembl release 55 and 3) Ensembl release 61. The
chromosomal location of B42 in Ensembl release 62 is highlighted
in green and labeled as ZNF578 pseudogene with surrounding
genes in the upper right, and the annotated exon structure is
shown below. B) N73. The coding region on exon 1 is indicated by
a filled box. The open reading frame is located on chromosome
8q24.3. The chromosomal location in Ensembl release 61 with
surrounding genes is shown in the upper right, and the exon
structure is shown below.
(TIF)
Table S1 Existing prediction tools applicable to chemo-
kine identification in comparison with our 3D profile-
based methodology (3D-CKpred). SP/TM: prediction of
signal peptides (SP) and transmembrane regions (TM); Batch:
processing of many sequences in one batch is supported (‘+’) or not
(‘2’); Seq/Str: sequence-based (seq) or a structure-based (str)
approach; diS: disulfide bond prediction based on 3D arrangement
of cysteine residues.
(DOC)
Table S2 Ten best candidate proteins selected for
atomic 3D model building and their respective thread-
ing results with the pdb95 fold library. The top (1-2)
chemokine threading hit obtained for each query protein is shown
including the PDB template structure used for their respective
molecular modelling. The ID of the proteins corresponding to the
four best 3D models selected for further refinement and analysis
are displayed in bold. ID: Protein name; UniProt: UniProt
identifier; Seq: sequence region selected; Rank: Top 1 or 2 ranking
of the chemokine fold in the threading control experiments across
fold space (pdb95 fold library); Thx: ProHit threading Index; %ID:
percentage of sequence identity between query and template;
Template: PDB template; PDB: template identifier in the Protein
Data Bank; Chain: template chain; fl: fold length; pl: path length;
diS: sequence number of cysteine residue pairs with possibilities of
disulfide bond formation.
(DOC)
Table S3 Transcription factor binding sites found in the
promoter region of the human and orangutan B42 genes.
Overview of transcription factor binding sites (TFBS) found in the
promoter region of the human and orangutan B42 genes with the
corresponding sequence pattern, its relative position to the
transcription start of the B42 gene, and chemokine genes known
to present those binding sites.
(DOC)
Table S4 Fold recognition results obtained for N73 with
the Chemokine fold library. Top 5 scoring structures are
shown. Rank: Rank of the template chemokine within all
chemokine structures in the fold library; Thx: threading index;
%ID: percentage of amino acid sequence identity between query
and template; pl: alignment path length; fl: template fold length;
PDB: template identifier in the Protein Data Bank; chain: template
chain; description: description of PDB template; UniProt: UniProt
identifier; Rec. agonist: Chemokine receptors for which the template
protein is an agonist; Rec. antagonist: Chemokine receptors for
which the template protein is an antagonist.
(DOC)
Table S5 Fold recognition results obtained for N73 with
the pdb95 fold library. Top 5 SCOP folds are shown. Conf:
Confidence level (HC, high confidence; FP, false positive); secr:
secretion; sse: all secondary structure elements present in
alignment; gap: gap length .10 amino acids; fcov: fold coverage
based on ratio of fold length/path length; Thx: threading index;
%ID: percentage of amino acid sequence identity between query
and template; pl: alignment path length; fl: template fold length;
SCOP: SCOP family identifier; PDB: template identifier in the
Protein Data Bank; chain: template chain; % cover.: percentage of
domain coverage; description: description of PDB template; Pfam:
Pfam description; UniProt: template UniProt identifier.
(DOC)
Table S6 Transcription factor binding sites found in the
promoter region of the human N73 gene. Overview of
transcription factor binding sites (TFBS) found in the promoter
region of the human N73 gene with the corresponding sequence
pattern, its relative position to the transcription start of the N73
gene, and chemokine genes known to present those binding sites.
(DOC)
Table S7 Threading results of CXCL17 with the pdb95
fold library. Only best template per SCOP fold is shown. The
chemokine fold is highlighted in bold. Abbreviations are the same
as in Table S5. Results obtained in CXCL identification [10] are
shown below for comparison.
(DOC)
Text S1
(DOC)
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